Microbiota and FMT in IBD: what a 2026 systematic review actually surveys

Two long-running conversations sit side by side for anyone living with ulcerative colitis or Crohn's disease — the two main forms of inflammatory bowel disease, both long-term and managed rather than cured [1][2]. One is about the gut microbiome: the idea that the community of bacteria, fungi, archaea and viruses living in the digestive tract is somehow involved in why the disease behaves the way it does [3]. The other is about fecal microbiota transplantation — FMT — the procedure that transfers a screened donor's stool into a recipient with the intention of restoring a healthier microbial community [4].

Both come up in clinic and in patient communities. Both are sometimes described as a quiet cure and sometimes dismissed as fringe. A 2026 systematic review published in Pathogens by a multinational gastroenterology group pulls the published literature on the two together [4]. The picture it draws is more careful than either of those extremes.

What the review actually did

It is a systematic review of the published literature on the role of the gut microbiota and fecal microbiota transplantation in inflammatory bowel disease [4]. The authors do not run a new clinical trial; they read what has been published, organise it, and assess what the field can and cannot yet say.

That posture matters when the topic is FMT. The procedure has captured public attention because the underlying idea is so vivid — the gut microbial community as something that can be repaired by introducing better neighbours. The job of a systematic review on this topic is exactly to step back from the vivid story and ask what the studies, in aggregate, actually show.

Microbiota in IBD — what the review describes

Across the studies the review surveys, alterations in the composition and diversity of the gut microbiota — described collectively as dysbiosis — are a consistent finding in people with ulcerative colitis and Crohn's disease compared with people without IBD [5]. Broadly, the patterns reported include lower microbial diversity, a relative shift in the balance between some bacterial groups, and a reduction in some bacteria thought to produce protective metabolites.

The careful sentence here is associated with, not causes. The microbiome differences are reproducible in research; whether they are a cause of the disease, a consequence of the inflammation it produces, or some mixture of the two is still being worked out. That distinction is doing quiet work in this whole topic. Treatments aimed at the microbiome only really make sense if you can change cause, not only consequence — and the field is not yet there with the kind of confidence a guideline would need.

FMT — what it works for, and where the evidence still sits

There is one place where FMT has moved past the research conversation and into clinical practice. For recurrent Clostridioides difficile infection — the difficult, often hospital-acquired bowel infection that returns after standard antibiotics — fecal microbiota-based therapy is now an established option, including in patients who also live with inflammatory bowel disease [6]. The 2024 AGA Clinical Practice Update on managing C. difficile in IBD treats it that way. This is the use case the wider public conversation about "stool transplant" is usually borrowing its credibility from.

What the Pathogens review is asking is a different question: what happens when FMT is studied not as a treatment for an infection sitting on top of IBD, but as a treatment for the underlying inflammatory bowel disease itself?

The review's reading of the published evidence is honest about its shape. FMT in IBD — outside of treating concurrent C. difficile — is described as an active area of research with promising signals but with the strongest evidence concentrated in ulcerative colitis, and with substantial heterogeneity in donor selection, route of delivery, dosing and frequency across the studies that have been done [7]. In Crohn's disease the evidence base is thinner still and harder to compare across studies.

That word heterogeneity is doing more work than it sounds. Different trials have used different donors, different preparations, different delivery routes (colonoscopy, enema, oral capsule), different schedules. Adding heterogeneous trials together does not give you a single answer about whether FMT works for ulcerative colitis; it gives you a noisy average over many slightly different procedures called by the same name. That is part of why an honest summary cannot yet say "FMT works in UC, here is the dose".

The careful conclusion

The review's overall conclusion is the one you would expect from a field at this stage. FMT is not currently part of standard treatment for inflammatory bowel disease, and further well-designed studies are needed to define which patients might benefit, what the protocol should actually look like, and how durable any benefit is over time [8]. That is not the same as "it doesn't work"; it is closer to "the question is still being asked properly".

What this might mean if you are tempted to try it

A few non-alarmist things worth taking from a paper like this if you or someone close to you has been reading about FMT online.

First, for ulcerative colitis or Crohn's disease, FMT is research, not standard care. There is genuine scientific interest, there are ongoing trials, there is a careful read of the evidence in reviews like this one. None of that adds up to a tested clinical service you can ask for the way you ask for a different IBD medication. If a gastroenterology team offers FMT as part of a clinical study, that is a defined and supervised setting; the same procedure outside that setting is something else entirely.

Second, do not source stool informally. Online communities sometimes describe DIY FMT, often with relatives as donors. The formal protocols this review describes screen donors carefully for transmissible infections and for other risk factors. Skipping that screening turns a procedure with a debatable benefit in IBD into a procedure with a clear potential to introduce a serious infection. That risk is well outside anything the published research is endorsing.

Third, the microbiome conversation is a good one to have with your IBD team, not a reason to substitute self-experiment for treatment. Diet, the medications you take, any current or future participation in a trial — those are reasonable things to raise during a routine review. Your gastroenterologist and IBD nurse specialist know your disease history, what has worked, what has not, and which trials might actually be appropriate for you. That conversation is the part of the microbiome story that has the most leverage.

The honest takeaway from a 2026 systematic review of this field is not a slogan in either direction. Microbiome differences in IBD are real and reproducible [5]. FMT works well for one specific infection that can co-occur with IBD [6]. For inflammatory bowel disease itself, the research is interesting and not yet settled [7][8]. We can make that distinction legible; only your IBD team can decide what, if anything, it means for your own care.